In particular, the expression values of TLR-2, TLR-3, TLR-4, and TLR-9 on CD3-CD56+ cells increased proportionally with the tumor stage, suggesting that these receptors may be functional as diagnostic and prognostic biomarkers in assessing the progression of GC. The gene discussed is NCAM1; the disease is gastric cancer.